Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc.verified

ACRS

Price:

$4.4883

Market Cap:

$541.27M

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moder...[Read more]

Industry

Medical - Diagnostics & Research

IPO Date

2015-10-06

Stock Exchange

NASDAQ

Ticker

ACRS

The Enterprise Value as of April 2026 (TTM) for Aclaris Therapeutics, Inc. (ACRS) is 523.42M

According to Aclaris Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 523.42M. This represents a change of 141.51% compared to the average of 216.73M of the last 4 quarters.

Aclaris Therapeutics, Inc. (ACRS) Historical Enterprise Value (quarterly & annually)

How has ACRS Enterprise Value performed in the past?

The mean historical Enterprise Value of Aclaris Therapeutics, Inc. over the last ten years is 389.41M. The current 523.42M Enterprise Value has changed 13.34% with respect to the historical average. Over the past ten years (40 quarters), ACRS's Enterprise Value was at its highest in in the March 2021 quarter at 1.24B. The Enterprise Value was at its lowest in in the March 2020 quarter at 488.17K.

Quarterly (TTM)
Annual

Average

389.41M

Median

307.90M

Minimum

33.85M

Maximum

982.53M

Aclaris Therapeutics, Inc. (ACRS) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Aclaris Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 493.51%

Maximum Annual Enterprise Value = 982.53M

Minimum Annual Increase = -96.56%

Minimum Annual Enterprise Value = 33.85M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2025351.38M110.25%
2024167.13M393.76%
202333.85M-96.56%
2022982.53M23.09%
2021798.21M201.87%
2020264.42M493.51%
201944.55M-79.44%
2018216.70M-55.25%
2017484.29M-12.11%
2016551.05M12.06%

Aclaris Therapeutics, Inc. (ACRS) Average Enterprise Value

How has ACRS Enterprise Value performed in the past?

The current Enterprise Value of Aclaris Therapeutics, Inc. (ACRS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

184.12M

5-year avg

466.62M

10-year avg

389.41M

Aclaris Therapeutics, Inc. (ACRS) Enterprise Value vs. Peers

How is ACRS’s Enterprise Value compared to its peers?

Aclaris Therapeutics, Inc.’s Enterprise Value is greater than Cabaletta Bio, Inc. (229.54M), greater than Exagen Inc. (64.48M), greater than Editas Medicine, Inc. (226.12M), greater than NeoGenomics, Inc. (498.84M), less than Owens & Minor, Inc. (2.24B), greater than Senseonics Holdings, Inc. (278.55M), less than Allogene Therapeutics, Inc. (553.45M), greater than MDxHealth S.A. (171.38M), greater than BioAge Labs, Inc. (432.65M), greater than 908 Devices Inc. (186.43M),

CompanyEnterprise ValueMarket cap
229.54M$285.43M
64.48M$69.03M
226.12M$296.06M
498.84M$236.45M
2.24B$207.07M
278.55M$277.73M
553.45M$521.88M
171.38M$105.30M
432.65M$615.98M
186.43M$252.31M

Build a custom stock screener for Aclaris Therapeutics, Inc. (ACRS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aclaris Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Aclaris Therapeutics, Inc. (ACRS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Aclaris Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Aclaris Therapeutics, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Aclaris Therapeutics, Inc. (ACRS)?

What is the 3-year average Enterprise Value for Aclaris Therapeutics, Inc. (ACRS)?

What is the 5-year average Enterprise Value for Aclaris Therapeutics, Inc. (ACRS)?

How does the current Enterprise Value for Aclaris Therapeutics, Inc. (ACRS) compare to its historical average?